Several companies expected to announce ‘most favored nation’ deals Friday at White Housenews2025-12-17T17:09:17+00:00December 17th, 2025|Endpoints News|
GSK formally submits new leucovorin indication to FDAnews2025-12-17T16:20:50+00:00December 17th, 2025|Endpoints News|
Padcev-Keytruda combination notches another bladder cancer winnews2025-12-17T16:07:05+00:00December 17th, 2025|Endpoints News|
RTW’s Yarrow to go public in reverse merger with Vyne Therapeuticsnews2025-12-17T15:47:20+00:00December 17th, 2025|Endpoints News|
Novo Nordisk hit with FDA warning letter over acquired Catalent factorynews2025-12-17T15:41:07+00:00December 17th, 2025|Endpoints News|
Vir licensing deal; Cytokinetics wins China nod; Vistagen’s social anxiety failnews2025-12-17T15:00:12+00:00December 17th, 2025|Endpoints News|
AI biotech preview of 2026: Clinic takes center stagenews2025-12-17T14:00:16+00:00December 17th, 2025|Endpoints News|
Post-Hoc Live: Endpoints winners and losers list for 2025news2025-12-17T13:48:27+00:00December 17th, 2025|Endpoints News|
Addition Therapeutics raises $106.5M for all RNA ‘jumping gene’ therapiesnews2025-12-17T13:22:29+00:00December 17th, 2025|Endpoints News|
Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney diseasenews2025-12-17T11:20:22+00:00December 17th, 2025|Endpoints News|
